Dr. Meir Glick, the Director of Informatics at Merck Research Laboratories, will present "A forward-looking strategy on how can chemistry and informatics enable biology" on Thursday, April 13th, starting at 6pm at Le Méridien Cambridge-MIT, 20 Sidney Street in Cambridge. Food, drinks, and networking will follow at Asgard, 350 Massachusetts Ave in Cambridge.
Please RSVP at to help us plan for this event.
This presentation describes how integration of screening, chemical synthesis and informatics can enable target identification and validation. More specifically, design of high quality molecular probes that perturb novel targets and phenotypes, creation of the most biologically relevant assays systems, progressing the right perturbagen into in vivo studies and eventually transforming the organization from data creators into decision makers.
Biography for Meir Glick
Dr. Glick is the Director of Informatics where he is responsible for the vision, strategy and delivery for a world class group that influences all of Merck Research. Before joining Merck in 2015 Dr. Glick was the head of the in silico Lead Discovery at the Novartis Institutes for BioMedical Research where he worked since 2003. He was a trained as a postdoc in the area of computational chemistry in the University of Oxford and received his PhD in computational chemistry from the Hebrew University of Jerusalem. Dr. Glick is the author of over 60 scientific papers in peer reviewed journals, patents and book chapters (https://scholar.google.com/citations?user=fwxyVs8AAAAJ&hl=en)
BAGIM is sponsored by Dassault Systemes, DNASTAR, LabAnswer, OpenEye Scientific, Schrodinger, Silicon Therapeutics, Acellera, Acpharis, Cambridge Crystallographic Data Centre, Chemical Computing Group, Cresset, Cyrus Biotechnology, Optibrium, Team Arrayo, and Scilligence